Answers are grounded in this paper and cite their sources.
A scalable 8-step route incorporating Evans auxiliary-assisted asymmetric 1,4-addition was developed for a key (S) -5-(2,2-dimethyltetrahydro-2 H -pyran-4-yl)-1 H -indole intermediate of orforglipron. The main challenges of the batch process included the copper complex’s stability, the high exothermicity of the reaction, and the control of a key diastereomeric impurity. These challenges were addressed by developing a CSTR process to prepare the copper complex, enabling “on-demand” preparation and improved heat transfer to control the reaction temperature. A simple slurry purification was devised to isolate a metastable polymorph that effectively reduced the diastereomeric impurity to acceptable levels. The optimized process was successfully scaled up to >400 kg, demonstrating its robustness.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: